Search
Summit Therapeutics Inc
SMMTAdd to Watchlist
13.105USD
-0.555-4.06%
Close 07-27 16:00（ET）Quotes delayed by 15 min
10.39BMarket Cap
LossP/E TTM
More Details of Summit Therapeutics Inc Company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Summit Therapeutics Inc Info
Ticker SymbolSMMT
Company nameSummit Therapeutics Inc
IPO dateOct 14, 2004
CEOZanganeh (Mahkam)
Number of employees159
Security typeOrdinary Share
Fiscal year-endOct 14
Address601 Brickell Key Drive
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33131
Phone13052032034
Websitehttps://www.smmttx.com/
Ticker SymbolSMMT
IPO dateOct 14, 2004
CEOZanganeh (Mahkam)
Company Executives of Summit Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
573.88M
+0.66%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
36.03M
+0.81%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
32.06M
+1.66%
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
573.88M
+0.66%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
36.03M
+0.81%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
32.06M
+1.66%
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Summit Therapeutics Inc?
The top five shareholders of Summit Therapeutics Inc are: Mr. Robert William (Bob) Duggan
How many institutions hold shares of Summit Therapeutics Inc (SMMT)?
As of 2026Q1, 554 institutions hold shares of Summit Therapeutics Inc, with a combined market value of approximately 122.68M, accounting for 15.81% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4361324.00.